The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List
Status unconfirmed · Not applicable
Conditions studied: Vitamin D Deficiency, Hepatocellular Carcinoma
In brief
The purpose of this study is to investigate the effect of two different doses of vitamin D3 (2000 IU vs. 4000 IU) on serum 25-hydroxyvitamin D (25OHD) levels in patients with hepatocellular carcinoma on the liver transplant list. The study will help determine the dose of vitamin D3 that is required for patients with liver cancer to reach a normal level of 25OHD in the blood.
Key facts
- Study ID
- NCT01575717
- Run by
- Andrea Branch
- People needed
- 50
- Starts
- 2012-01-01
- Expected to finish
- 2013-01-01
- Last updated by the study team
- 2012-10-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult patients (18 years and older)
- Diagnosis of hepatocellular carcinoma
- On the list awaiting liver transplantation
- Able to give informed consent
- Expected to receive care following liver transplantation at the Mount Sinai School of Medicine
- Any race/ethnicity/socioeconomic status
You may not qualify if…
- Pediatric patient (less than 18 years of age)
- Unable to give informed consent
- Untreated primary hyperparathyroidism (ICD9 codes 252.01XX and 252.00XX)
- Untreated hypercalcemia (serum calcium level > 11 mg/dl; ICD9 codes 275.42XX, 259.3XX, 252.00F)
- Pregnancy (will be determined by asking the patient and reviewing the medical record)
Where it is running
- The Mount Sinai Hospital — New York, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.